Based on: Psoriatic Arthritis — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 8 October 2026; the tracker page is the live version.
Short answer: as of October 2026, the OSMF Research Tracker lists 51 candidate interventions for psoriatic Arthritis that are either approved medicines or have at least one registered clinical trial, built on 7 druggable gene targets, with 14 recent trials on ClinicalTrials.gov. 11 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- Secukinumab — 9 registered trials · approved medicine · NCT06751238 NCT02721966 NCT01989468
- Adalimumab — 6 registered trials · approved medicine · NCT03104400 NCT03895203 NCT02745080
- Methotrexate — 5 registered trials · approved medicine · NCT03402087 NCT07086924 NCT01313858
- Etanercept — 4 registered trials · approved medicine · NCT02376790 NCT00962741 NCT03955861
- Guselkumab — 4 registered trials · approved medicine · NCT05049798 NCT02103361 NCT04882098
- Bimekizumab — 4 registered trials · investigational · NCT03896581 NCT06668181 NCT04009499
- Risankizumab — 3 registered trials · approved medicine · NCT03675308 NCT04846959 NCT02719171
- Apremilast — 2 registered trials · approved medicine · NCT03828045 NCT02775500
- golimumab — 2 registered trials · approved medicine · NCT01081717 NCT03955861
- Ixekizumab — 2 registered trials · approved medicine · NCT02584855 NCT04527380
- Ustekinumab — 2 registered trials · approved medicine · NCT03881059 NCT02103361
- Deucravacitinib — 2 registered trials · investigational · NCT07280702 NCT06869551
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in psoriatic Arthritis and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: CTLA4, IL17A, IL23A, IL23R, JAK1, PDE4D, TNF.
Which trials are registered?
- A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis NCT03773965 · Recruiting · Phase PHASE3 · started 2019-04-05
- A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis NCT06869551 · Recruiting · Phase PHASE3 · started 2025-03-13
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO NCT03816345 · Recruiting · Phase PHASE1 · started 2019-07-16
- Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control Study. NCT07858591 · Recruiting · Phase NA · started 2026-09-01
- Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis NCT04804553 · Recruiting · Phase PHASE3 · started 2022-03-17
- A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically NCT07654751 · Recruiting · Phase PHASE4 · started 2026-08-07
- Regulation of Mucosal Healing in Inflammatory Bowel Disease NCT04504136 · Completed · Phase NA · started 2021-04-30
- Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). NCT06751238 · Recruiting · Phase PHASE1 · started 2025-09-24
- A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis NCT03895203 · Completed · Phase PHASE3 · started 2019-04-03
- Modifying PEST for Psoriatic Arthritis Screening NCT06382051 · Recruiting · Phase NA · started 2025-01-23
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take.
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 8 October 2026.